Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis

Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease

(2018) Gemma L. Nixon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis

(2017) Radha Rajasingham et al.   LANCET INFECTIOUS DISEASES

The Anti-helminthic Compound Mebendazole Has Multiple Antifungal Effects against Cryptococcus neoformans

(2017) Luna S. Joffe et al.   Frontiers in Microbiology

Synergy and antagonism between iron chelators and antifungal drugs in Cryptococcus

(2016) Yu-Wen Lai et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Novel cell-based in vitro screen to identify small-molecule inhibitors against intracellular replication of Cryptococcus neoformans in macrophages

(2016) Sweta Samantaray et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Global access to antifungal therapy and its variable cost

(2016) Matthew Kneale et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study

(2016) Joshua Rhein et al.   LANCET INFECTIOUS DISEASES

Synergistic Effect of Fluconazole and Calcium Channel Blockers against Resistant Candida albicans

(2016) Shuyuan Liu et al.   PLoS One

Prevalence and Hospital Management of Amphotericin B Deoxycholate-Related Toxicities during Treatment of HIV-Associated Cryptococcal Meningitis in South Africa

(2016) Susan Meiring et al.   PLoS Neglected Tropical Diseases

Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda

(2015) Kyle D. Smith et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Recognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex

(2015) Ferry Hagen et al.   FUNGAL GENETICS AND BIOLOGY

A high-throughput screening assay for assessing the viability of Cryptococcus neoformans under nutrient starvation conditions

(2013) Seameen J. Dehdashti et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Determinants of Mortality in a Combined Cohort of 501 Patients With HIV-Associated Cryptococcal Meningitis: Implications for Improving Outcomes

(2013) Joseph N. Jarvis et al.   CLINICAL INFECTIOUS DISEASES

Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal

(2013) A. Loyse et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Drug Repurposing: Far Beyond New Targets for Old Drugs

(2012) T. I. Oprea et al.   AAPS Journal

Prevalence of cryptococcosis among HIV-infected patients in Yaounde, Cameroon

(2012) JF Dzoyem et al.   African Health Sciences

The Antidepressant Sertraline Provides a Promising Therapeutic Option for Neurotropic Cryptococcal Infections

(2012) Bing Zhai et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of the Calcium Channel Pore Cch1 Is Dependent on a Modulatory Region of the Subunit Mid1 in Cryptococcus neoformans

(2012) Min-Pyo Hong et al.   EUKARYOTIC CELL

A Repurposing Approach Identifies Off-Patent Drugs with Fungicidal Cryptococcal Activity, a Common Structural Chemotype, and Pharmacological Properties Relevant to the Treatment of Cryptococcosis

(2012) Arielle Butts et al.   EUKARYOTIC CELL

Identification and Analysis of Cation Channel Homologues in Human Pathogenic Fungi

(2012) David L. Prole et al.   PLoS One

Microtubules as antifungal and antiparasitic drug targets

(2011) Biswa Prasun Chatterji et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole

(2011) M. Spitzer et al.   Molecular Systems Biology

Voltage-Gated Calcium Channels

(2011) W. A. Catterall   Cold Spring Harbor Perspectives in Biology

The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma

(2010) P. A. Spagnuolo et al.   BLOOD

Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America

(2010) John R. Perfect et al.   CLINICAL INFECTIOUS DISEASES

Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect

(2010) B. Zhai et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Cch1 Restores Intracellular Ca2+in Fungal Cells during Endoplasmic Reticulum Stress

(2010) Min-Pyo Hong et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

In Vitro Susceptibility of the Yeast Pathogen Cryptococcus to Fluconazole and Other Azoles Varies with Molecular Genotype

(2010) H. S. Chong et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Emergence and Pathogenicity of Highly Virulent Cryptococcus gattii Genotypes in the Northwest United States

(2010) Edmond J. Byrnes et al.   PLoS Pathogens

Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS

(2009) Benjamin J Park et al.   AIDS

Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces

(2009) Andrea C. Cumino et al.   PARASITOLOGY INTERNATIONAL

Flubendazole in cystic echinococcosis therapy: Pharmaco-parasitological evaluation in mice

(2009) Laura Ceballos et al.   PARASITOLOGY INTERNATIONAL

Ion-channel blocker sensitivity of voltage-gated calcium-channel homologue Cch1 in Saccharomyces cerevisiae

(2008) J. Teng et al.   MICROBIOLOGY-SGM